{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:27:44Z","timestamp":1792787264298,"version":"4.5.0"},"reference-count":82,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Medical Health Research Council Australia"},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,4,14]]},"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Bloodstream infections are a leading cause of mortality and morbidity; the duration of treatment for these infections is understudied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      We will conduct an international, multicentre randomised clinical trial of shorter (7 days) versus longer (14 days) antibiotic treatment among hospitalised patients with bloodstream infections. The trial will include 3626 patients across 60 hospitals and 6 countries. We will include patients with blood cultures confirming a pathogenic bacterium after hospital admission. Exclusion criteria will include patient factors (severe immunosuppression), infection site factors (endocarditis, osteomyelitis, undrained abscesses, infected prosthetic material) and pathogen factors (\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      ,\n                      <jats:italic>Staphylococcus lugdunensis<\/jats:italic>\n                      ,\n                      <jats:italic>Candida<\/jats:italic>\n                      and contaminant organisms). We will leave the selection of specific antibiotics, doses and route of delivery to the discretion of treating physicians; no placebo control will be used given the diversity of pathogens and sources of bacteraemia. The intervention will be assignment of treatment duration to be 7 versus 14 days. We will minimise selection bias via central randomisation with variable block sizes, with concealed allocation until day 7 of adequate antibiotic treatment. The primary outcome is 90-day survival; we will test whether 7 days is non-inferior to 14 days of treatment, with a non-inferiority margin of 4% absolute mortality. Secondary outcomes include hospital and intensive care unit (ICU) mortality, relapse rates of bacteraemia, hospital and ICU length of stay, mechanical ventilation and vasopressor duration, antibiotic-free days,\n                      <jats:italic>\n                        C\n                        <jats:italic>lostridium<\/jats:italic>\n                        difficile\n                      <\/jats:italic>\n                      infection, antibiotic allergy and adverse events and colonisation\/infection with antibiotic-resistant organisms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study has been approved by the ethics review board at each participating site. Sunnybrook Health Sciences Centre is the central ethics committee. We will disseminate study results via the Canadian Critical Care Trials Group and other collaborating networks to set the global paradigm for antibiotic treatment duration for non-staphylococcal Gram-positive, Gram-negative and anaerobic bacteraemia, among patients admitted to hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      The BALANCE (Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness) trial was registered at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"www.clinicaltrials.gov\">www.clinicaltrials.gov<\/jats:ext-link>\n                      (registration number:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03005145\">NCT03005145<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-038300","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T06:17:04Z","timestamp":1589264224000},"page":"e038300","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) randomised clinical trial: study protocol"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03005145","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02261506","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02917551","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8827-3764","authenticated-orcid":false,"given":"Nick","family":"Daneman","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases & Clinical Epidemiology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asgar H","family":"Rishu","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxandra L","family":"Pinto","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaseen M","family":"Arabi","sequence":"additional","affiliation":[{"name":"Intensive Care Department, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J","family":"Cook","sequence":"additional","affiliation":[{"name":"McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hall","sequence":"additional","affiliation":[{"name":"Departments of Critical Care Medicine and Anesthesiology, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shay","family":"McGuinness","sequence":"additional","affiliation":[{"name":"Auckland City Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Muscedere","sequence":"additional","affiliation":[{"name":"Kingston General Hospital, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Parke","sequence":"additional","affiliation":[{"name":"The University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Royal Columbian Hospital, New Westminster, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Rogers","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Diseases, Monash University School of Clinical Sciences, Melborne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya","family":"Shehabi","sequence":"additional","affiliation":[{"name":"Critical Care and Perioperative Medicine, School of Clinical Sciences, Monash University and Monash Health, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Fowler","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,5,11]]},"reference":[{"key":"2025121411123273000_10.5.e038300.1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12195"},{"key":"2025121411123273000_10.5.e038300.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1754"},{"key":"2025121411123273000_10.5.e038300.3","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.163.7.9912080"},{"key":"2025121411123273000_10.5.e038300.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510440058033"},{"key":"2025121411123273000_10.5.e038300.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2005.12.016"},{"key":"2025121411123273000_10.5.e038300.6","first-page":"107","article-title":"Microbiological surveillance and parenteral antibiotic use in a critical care unit","volume":"11","author":"Yamashita","year":"2000","journal-title":"Can J Infect Dis"},{"key":"2025121411123273000_10.5.e038300.7","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.8.972"},{"key":"2025121411123273000_10.5.e038300.8","doi-asserted-by":"publisher","DOI":"10.1086\/510393"},{"key":"2025121411123273000_10.5.e038300.9","doi-asserted-by":"publisher","DOI":"10.1086\/591126"},{"key":"2025121411123273000_10.5.e038300.10","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1099"},{"key":"2025121411123273000_10.5.e038300.11","doi-asserted-by":"publisher","DOI":"10.1086\/526535"},{"key":"2025121411123273000_10.5.e038300.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.08.016"},{"key":"2025121411123273000_10.5.e038300.13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jamainternmed.2013.3029","article-title":"Prolonged antibiotic treatment in long-term care: role of the prescriber","volume":"173","author":"Daneman","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2025121411123273000_10.5.e038300.14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir301"},{"key":"2025121411123273000_10.5.e038300.15","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31821b85f4"},{"key":"2025121411123273000_10.5.e038300.16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.idc.2009.01.009","article-title":"Meta-Analyses on the optimization of the duration of antimicrobial treatment for various infections","volume":"23","author":"Rafailidis","year":"2009","journal-title":"Infect Dis Clin North Am"},{"key":"2025121411123273000_10.5.e038300.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.19.2588"},{"key":"2025121411123273000_10.5.e038300.18","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31819285f0"},{"key":"2025121411123273000_10.5.e038300.19","doi-asserted-by":"publisher","DOI":"10.1186\/cc10545"},{"key":"2025121411123273000_10.5.e038300.20","unstructured":"Yahav D , Franceschini E , Koppel F , et al . Seven versus fourteen days of antibiotic therapy for uncomplicated gram-negative bacteremia: a non-inferiority randomized controlled trial. Clin Infect Dis 2018."},{"key":"2025121411123273000_10.5.e038300.21","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/cid\/ciy1057","article-title":"Shortening antibiotic treatment durations for bacteremia","volume":"69","author":"Daneman","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025121411123273000_10.5.e038300.22","doi-asserted-by":"publisher","DOI":"10.1086\/511159"},{"key":"2025121411123273000_10.5.e038300.23","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-644ST"},{"key":"2025121411123273000_10.5.e038300.24","doi-asserted-by":"publisher","DOI":"10.1086\/649554"},{"key":"2025121411123273000_10.5.e038300.25","doi-asserted-by":"publisher","DOI":"10.1086\/599376"},{"key":"2025121411123273000_10.5.e038300.26","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"2025121411123273000_10.5.e038300.27","doi-asserted-by":"publisher","DOI":"10.1086\/497143"},{"key":"2025121411123273000_10.5.e038300.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.07.016"},{"key":"2025121411123273000_10.5.e038300.29","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijantimicag.2019.05.011","article-title":"Duration of therapy recommended for bacteraemic illness varies widely amongst clinicians","volume":"54","author":"Alwan","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2025121411123273000_10.5.e038300.30","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/141989"},{"key":"2025121411123273000_10.5.e038300.31","unstructured":"Daneman N , Rishu AH , Xiong W , et al . Antibiotic treatment durations among Canadian critically ill patients with bacteremia. In Submission AJRCCM 2014."},{"key":"2025121411123273000_10.5.e038300.32","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-018-2474-1","article-title":"7 versus 14\u00a0days of antibiotic treatment for critically ill patients with bloodstream infection: a pilot randomized clinical trial","volume":"19","author":"Daneman","year":"2018","journal-title":"Trials"},{"key":"2025121411123273000_10.5.e038300.33","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-019-4033-9","article-title":"A pilot randomized controlled trial of 7 versus 14\u2009days of antibiotic treatment for bloodstream infection on non-intensive care versus intensive care wards","volume":"21","author":"Daneman","year":"2020","journal-title":"Trials"},{"key":"2025121411123273000_10.5.e038300.34","unstructured":"Clinical and Laboratory Standards Institute . Principles and procedures for blood Cutlures; Approved guideline M47-A. No. 17. 201127."},{"key":"2025121411123273000_10.5.e038300.35","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70285-1"},{"key":"2025121411123273000_10.5.e038300.36","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-015-0688-z","article-title":"Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): study protocol for a pilot randomized controlled trial","volume":"16","author":"Daneman","year":"2015","journal-title":"Trials"},{"key":"2025121411123273000_10.5.e038300.37","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.15.1669"},{"key":"2025121411123273000_10.5.e038300.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60608-4"},{"key":"2025121411123273000_10.5.e038300.39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1988.tb15899.x","article-title":"One or three weeks' treatment of acute pyelonephritis? A double-blind comparison, using a fixed combination of pivampicillin plus pivmecillinam","volume":"223","author":"Jernelius","year":"1988","journal-title":"Acta Med Scand"},{"key":"2025121411123273000_10.5.e038300.40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38049.490255.DE"},{"key":"2025121411123273000_10.5.e038300.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09994-4"},{"key":"2025121411123273000_10.5.e038300.42","doi-asserted-by":"publisher","DOI":"10.1086\/377539"},{"key":"2025121411123273000_10.5.e038300.43","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh356"},{"key":"2025121411123273000_10.5.e038300.44","article-title":"Measuring the duration of adequate antimicrobial treatment in critical care","volume":"189","author":"Craig","year":"2014","journal-title":"J Thorac Dis"},{"key":"2025121411123273000_10.5.e038300.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2012.12.005"},{"key":"2025121411123273000_10.5.e038300.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0883-9441(98)90000-4"},{"key":"2025121411123273000_10.5.e038300.47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61879-1"},{"key":"2025121411123273000_10.5.e038300.48","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-208466"},{"key":"2025121411123273000_10.5.e038300.49","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1097\/CCM.0000000000003904","article-title":"A core outcome set for critical care ventilation trials","volume":"47","author":"Blackwood","year":"2019","journal-title":"Crit Care Med"},{"key":"2025121411123273000_10.5.e038300.50","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70035-4"},{"key":"2025121411123273000_10.5.e038300.51","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001393"},{"key":"2025121411123273000_10.5.e038300.52","doi-asserted-by":"publisher","DOI":"10.2307\/2530245"},{"key":"2025121411123273000_10.5.e038300.53","unstructured":"Jennison C , Turnbull B . Group sequential methods with applications to clinical trials. Chapman and Hall, 2015."},{"key":"2025121411123273000_10.5.e038300.54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040232"},{"key":"2025121411123273000_10.5.e038300.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199902113400601"},{"key":"2025121411123273000_10.5.e038300.56","unstructured":"United States Deaprtment of Health and Human Services . Guidance for industry non-inferiority clinical trials 2010."},{"key":"2025121411123273000_10.5.e038300.57","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N Engl J Med"},{"key":"2025121411123273000_10.5.e038300.58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014475"},{"key":"2025121411123273000_10.5.e038300.59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215554"},{"key":"2025121411123273000_10.5.e038300.60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052904"},{"key":"2025121411123273000_10.5.e038300.61","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c869"},{"key":"2025121411123273000_10.5.e038300.62","doi-asserted-by":"publisher","DOI":"10.1001\/2012.jama.11235"},{"key":"2025121411123273000_10.5.e038300.63","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7365.652"},{"key":"2025121411123273000_10.5.e038300.64","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2018.14276","article-title":"Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a randomized clinical trial","volume":"320","author":"Goligher","year":"2018","journal-title":"JAMA"},{"key":"2025121411123273000_10.5.e038300.65","doi-asserted-by":"crossref","unstructured":"Spiegelhalter DJ , Abrams KR . Bayesian approaches to clinical trials and health-care evaluation. John Wiley & Sons, 2004.","DOI":"10.1002\/0470092602"},{"key":"2025121411123273000_10.5.e038300.66","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jama.2019.1198","article-title":"Post hoc Bayesian analyses","volume":"321","author":"Aberegg","year":"2019","journal-title":"JAMA"},{"key":"2025121411123273000_10.5.e038300.67","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.87802"},{"key":"2025121411123273000_10.5.e038300.68","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s12561-017-9200-5","article-title":"Bayesian design of non-inferiority clinical trials via the Bayes factor","volume":"10","author":"Li","year":"2018","journal-title":"Stat Biosci"},{"key":"2025121411123273000_10.5.e038300.69","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-019-0699-7","article-title":"Bayes factors for superiority, non-inferiority, and equivalence designs","volume":"19","author":"van Ravenzwaaij","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"2025121411123273000_10.5.e038300.70","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1927"},{"key":"2025121411123273000_10.5.e038300.71","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-2607(02)00120-7"},{"key":"2025121411123273000_10.5.e038300.72","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17965-3"},{"key":"2025121411123273000_10.5.e038300.73","doi-asserted-by":"crossref","first-page":"533.e11","DOI":"10.1016\/j.jcrc.2010.12.009","article-title":"Consent in critical care trials: a survey of Canadian research ethics boards and critical care researchers","volume":"26","author":"Duffett","year":"2011","journal-title":"J Crit Care"},{"key":"2025121411123273000_10.5.e038300.74","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1007\/s00134-013-2990-0","article-title":"Research to inform the consent-to-research process","volume":"39","author":"Scales","year":"2013","journal-title":"Intensive Care Med"},{"key":"2025121411123273000_10.5.e038300.75","doi-asserted-by":"crossref","unstructured":"Smith OM , McDonald E , Zytaruk N , et al . Enhancing the informed consent process for critical care research: strategies from a thromboprophylaxis trial. Intensive Crit Care Nurs 2013.","DOI":"10.1016\/j.iccn.2013.04.006"},{"key":"2025121411123273000_10.5.e038300.76","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jcrc.2012.08.005","article-title":"Rates and determinants of informed consent: a case study of an international thromboprophylaxis trial","volume":"28","author":"Smith","year":"2013","journal-title":"J Crit Care"},{"key":"2025121411123273000_10.5.e038300.77","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.iccn.2013.04.006","article-title":"Enhancing the informed consent process for critical care research: strategies from a thromboprophylaxis trial","volume":"29","author":"Smith","year":"2013","journal-title":"Intensive Crit Care Nurs"},{"key":"2025121411123273000_10.5.e038300.78","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00627-10"},{"key":"2025121411123273000_10.5.e038300.79","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000217961.75225.E9"},{"key":"2025121411123273000_10.5.e038300.80","first-page":"32","article-title":"Antimicrobial cost savings associated with shorter duration treatment for bloodstream infections","volume":"1","author":"Daneman","year":"2017","journal-title":"JAMMI"},{"key":"2025121411123273000_10.5.e038300.81","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j3418"},{"key":"2025121411123273000_10.5.e038300.82","doi-asserted-by":"crossref","unstructured":"Meier MA , Branche A , Neeser OL , et al . Procalcitonin-guided antibiotic treatment in patients with positive blood cultures: a patient-level meta-analysis of randomized trials. Clin Infect Dis 2018.","DOI":"10.1093\/cid\/ciy917"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-038300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:12:43Z","timestamp":1765739563000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-038300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":82,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,11]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1136\/bmjopen-2020-038300"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-038300","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}